Science at Sanofi

video of Pr Steven Edelman answering to the question: How has Toujeo®’s wall of evidence across diverse diabetes patient populations and situations helped to inform your clinical decision making?

Perspectives on basal insulin use post-GLP-1 RA, EASD, Dr Alice Cheng

What for you are the key findings of the Toujeo® pooled analysis?

In what way does the evidence for Toujeo^® help you to address the considerations for patients who are inadequately controlled on a GLP-1 receptor agonist?

How does the Toujeo pooled analysis complement DELIVER-G Study

What would you say is the value of the findings in the Toujeo^® pooled analysis and the DELIVER-G study when you consider the management of your patients with type 2 diabetes who are inadequately controlled on GLP-1 receptor agonist?

The Soli-Switch Study evaluates the real-world effectiveness and safety of switching adults with type 2 diabetes from basal insulin or GLP-1 RA therapy to iGlarLixi (insulin glargine 100 U/mL plus lixisenatide). The study explores glycaemic control, treatment adherence, and patient outcomes in clinical practice settings.

Explore the clinical considerations and practical implications of switching people living with diabetes (PWD) from human insulin to analogue insulin. This discussion highlights the rationale for switching, including clinical indications, availability, and access challenges.